IOL Chemicals and Pharmaceuticals Limited (IOLCP.BO)
- Previous Close
86.43 - Open
86.23 - Bid 86.28 x --
- Ask --
- Day's Range
85.56 - 88.22 - 52 Week Range
57.51 - 107.41 - Volume
116,718 - Avg. Volume
112,803 - Market Cap (intraday)
25.326B - Beta (5Y Monthly) 0.55
- PE Ratio (TTM)
25.08 - EPS (TTM)
3.44 - Earnings Date Aug 7, 2025 - Aug 11, 2025
- Forward Dividend & Yield 0.80 (0.93%)
- Ex-Dividend Date Feb 18, 2025
- 1y Target Est
89.30
IOL Chemicals and Pharmaceuticals Limited manufactures and sells pharmaceutical and chemical products in India and internationally. The company offers active pharmaceutical ingredients (API), such as ibuprofen lysinate and ibuprofen sodium; and other APIs, including metformin, fenofibrate, lamotrigine, clopidogrel bisulphate, pantoprazole, gabapentin, levetiracetam, paracetamol, etc. Its active pharmaceutical ingredients are used for the treatment of anti-inflammatory, analgesic and antipyretic, anti-diabetic, anti- platelet, anti-cholesterol, anti- convulsant, and anti-cholelithic, as well as proton pump inhibitor. IOL Chemicals and Pharmaceuticals Limited provides specialty industrial chemicals comprising ethyl acetate, iso butyl benzene, acetyl chloride, para amino phenol, and mono chloro acetic acid to food processing, flexible packaging, pharmaceuticals, textiles, ink, paint, pesticides, and chemical intermediates industries. IOL Chemicals and Pharmaceuticals Limited was incorporated in 1986 and is based in Ludhiana, India.
www.iolcp.com--
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: IOLCP.BO
View MorePerformance Overview: IOLCP.BO
Trailing total returns as of 5/23/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: IOLCP.BO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: IOLCP.BO
View MoreValuation Measures
Market Cap
25.37B
Enterprise Value
24.37B
Trailing P/E
25.12
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.22
Price/Book (mrq)
1.50
Enterprise Value/Revenue
1.17
Enterprise Value/EBITDA
10.84
Financial Highlights
Profitability and Income Statement
Profit Margin
4.86%
Return on Assets (ttm)
3.52%
Return on Equity (ttm)
6.13%
Revenue (ttm)
20.79B
Net Income Avi to Common (ttm)
1.01B
Diluted EPS (ttm)
3.44
Balance Sheet and Cash Flow
Total Cash (mrq)
2.11B
Total Debt/Equity (mrq)
6.93%
Levered Free Cash Flow (ttm)
-388.81M